Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I, single-arm, open-label, multi-center study of rising doses of Troxatyl™
whose purpose is to determine the safety, tolerance, and pharmacokinetics, and to establish
the recommended infusion schedule of Troxatyl™.